ZUG, Switzerland, Oct. 29, 2025 — Galderma is experiencing one of its strongest years yet. The company, long known for its dermatology and aesthetic care products, has seen a remarkable surge in sales thanks to Nemluvio, its new biologic therapy for prurigo nodularis and atopic dermatitis. In the first nine months of 2025, Nemluvio generated around 260 million dollars in revenue, with most of that growth coming from the United States.

Encouraged by this performance, Galderma has raised its full-year growth forecast from an earlier estimate of 12 to 14 percent to about 17 percent. This confidence reflects both the success of Nemluvio and the strength of Galderma’s broader skin health portfolio. The company is no longer seen only as a skincare brand. It is now firmly positioning itself among the leading global players in dermatological innovation.

Why Focus on the United States?

The U.S. market has become the heart of Galderma’s business expansion. Demand for advanced dermatology treatments is rising quickly, and Nemluvio’s approval has opened new opportunities. Patients with chronic inflammatory skin diseases often face limited treatment choices. Nemluvio offers relief in cases where other options have failed, which explains its rapid uptake among U.S. dermatologists.

Galderma’s U.S. sales have grown by about 17 percent year on year, outpacing performance in other regions. The company’s management sees this as a signal to invest directly where the demand is strongest. Building production capacity in the U.S. means less dependence on European facilities and shorter supply chains. It also helps Galderma navigate potential tariff risks while improving delivery timelines.

The decision to commit more than 650 million dollars through 2030 is not just a short-term response to Nemluvio’s success. It is a long-term play that ties directly to the company’s ambition to make the U.S. a key manufacturing and innovation hub for dermatology.

What Exactly is Galderma Building?

Strengthening Manufacturing and Supply Chain Capacity: The company plans to expand its network of production and packaging facilities within the United States. This includes transferring technology to U.S.-based contractors and potentially developing new in-house capabilities. Local production will support Nemluvio and other fast-growing brands such as Cetaphil and Alastin. The idea is to create a more flexible and resilient supply system that can scale with demand.

Investing in Aesthetics and Advanced Treatments: Galderma is also broadening its presence in medical aesthetics. Products in its neuromodulator and injectable portfolio are gaining traction, particularly in the U.S. By anchoring manufacturing closer to the market, Galderma is preparing for growth across both its therapeutic and aesthetic divisions. This two-track strategy strengthens the company’s position as a full-spectrum skin health leader rather than a single-product business.

Can This Expansion Handle the Risks?

Every large-scale investment brings uncertainty, and Galderma’s move is no exception. Building or expanding production facilities in another country involves regulatory challenges, cost inflation, and operational risk. The company must also manage complex supply requirements for biologic products, which demand strict quality controls and consistency.

Tariffs on Swiss exports to the U.S. remain a concern, though the company’s executives have described the current impact as manageable. By producing locally, Galderma aims to offset those costs and reduce exposure to future trade disruptions.

Competition is another factor. The dermatology space is becoming more crowded as other pharmaceutical players develop biologics for similar conditions. Galderma’s early success with Nemluvio gives it a strong foothold, but maintaining leadership will require continued innovation and reliable product supply.

Still, Galderma appears well prepared. The company’s strategic timing means it is reinvesting profits from Nemluvio’s sales while the product is gaining traction. This allows the company to fund expansion from a position of strength rather than necessity.

A Broader Message for the Industry

Galderma’s manufacturing investment reflects a wider trend among life sciences companies. Many are choosing to bring production closer to their key markets rather than depending entirely on global supply chains. The shift helps improve efficiency, manage risks, and meet patient needs more quickly.

For dermatology patients in the U.S., this could mean better access to new treatments and fewer supply interruptions. For healthcare providers, it signals stronger support from manufacturers who understand the need for speed and reliability. And for investors, Galderma’s decision demonstrates how a successful product launch can translate into a sustainable industrial strategy.

The company’s raised growth outlook and renewed focus on the U.S. also support its longer-term goals, which could include a future public offering. Strong operational control and visible investment in local capacity strengthen its reputation as a serious global contender in both dermatology and aesthetics.

Galderma’s decision to invest heavily in U.S. manufacturing is not just a reaction to a successful product launch. It is a sign of confidence in a market that is shaping the company’s next chapter. Nemluvio’s surge has given Galderma the momentum and the means to build a stronger base for future innovation. By tying manufacturing growth directly to rising demand, the company is showing that strategic investment can turn short-term success into long-term resilience.